Quantcast

Industry news that matters to you.  Learn more

National Cancer Institute Awards Labcyte $1 Million for Novel High-Throughput Cancer Biomarker Detection

Labcyte Inc., the acoustic dispensing company, has been awarded $1 million to create an innovative process to detect cancer-related proteins in samples, with initial work in breast cancer detection. The unsurpassed precision and accuracy of Labcyte acoustic liquid handling enables biomarker detection by measuring multiple proteins with a MALDI mass spectrometer.

The Ongoing Collaboration Aims to Exploit the High Throughput, Robustness and Ease of Use of MALDI-TOF Instruments

At the 12th HUPO World Congress, Bruker Corporation (NASDAQ: BRKR) recently announced the start of a second-phase collaboration agreement with SISCAPA Assays Technologies, Inc. (SAT). The ongoing collaboration aims to exploit the high throughput, robustness and ease of use of MALDI-TOF instruments as an alternative to nano-LC-MS technology currently used in many SISCAPA assays.

Identification of Differential Proteins in Maternal Serum with Down Syndrome

Prenatal screening for Down syndrome (DS) is still in need of improvement. Perinatal medicine experts have worked hard to find new biomarkers for screening of DS. Dr. Shi he Shao and his co-investigators, from Jiangsu University and Changzhou Woman and Children Health Hospital, report in the May 2012 issue of Experimental Biology and Medicine that they have successfully identified twenty-nine differentially expressed proteins in maternal serum from pregnancies carrying DS fetuses with proteomic approaches. These differential proteins offer the possibility of improving the performance of DS screening in the future. The functional roles of these proteins also possibly have a relationship with the development of DS.

Bruker and SISCAPA Assay Technologies Announce Joint Publication on SISCAPA-MALDI-TOF Mass Spectrometry for Biomarker Validation and Clinical Research

Bruker Corporation and SISCAPA Assay Technologies, Inc. (SAT) today announced the publication of a study in the Journal of Proteome Research demonstrating that SISCAPA MALDI-TOF mass spectrometry provides excellent precision for quantitation of proteins of interest, such as high value protein biomarkers. The publication results from an ongoing collaboration between Bruker and SAT to develop MALDI-TOF as a high precision and high throughput mass spectrometric detection method for SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) assays.

Labcyte Secures NIH Funding for Advanced Biomarker Validation Program in Collaboration with Stanford University

Labcyte Inc. today announced the award of $196K from the National Cancer Institute to fund a collaborative cancer biomarker validation program with the Canary Center of Stanford University. The program will develop an advanced system for early cancer detection by integrating a suite of well-established biotechnologies that includes Labcyte proprietary acoustic liquid handling for arraying and MALDI mass spectrometry preparation.